Optimizing surveillance and balancing evidence with patient expectations.
For most cancers, intensive posttreatment surveillance does not improve survival, but can induce anxiety in patients and may lead to unnecessary testing due to false-positive results. For colorectal cancer, more intensive surveillance, especially during the first few survivorship years, is warranted. For breast cancer, surveillance for second primary cancers with annual mammography is warranted. This may also be the case for non-small cell lung cancer. For other tumors, less routine surveillance testing can be recommended.
Presented by Crystal Denlinger, MD, Assistant Professor, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Crystal
C
Denlinger
Presented by Crystal Denlinger, MD, Assistant Professor, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Terry S
TS
Langbaum
D005500:Follow-Up Studies; D006801:Humans; D008495:Medical Oncology; D009369:Neoplasms / Q000175:diagnosis / Q000628:therapy